Cell and Gene Therapy Explained: Breakthrough Treatments, Risks, and The Road Ahead (2026)

Cell and gene therapy covers two related treatment types: cell therapy transfers specific cells into a person, while gene therapy uses genes to correct genetic problems. Cell-based gene therapy, such as CAR T, combines both approaches.

The healthcare hub that answers how is biotechnology used in medicine gives the wider context. This page covers how the two approaches differ, which products are approved, what the main risks are and why cost and access remain hard.

How cell therapy and gene therapy differ

The core difference is what goes into the patient. Cell therapy delivers living cells. Gene therapy delivers or edits genetic instructions. The two overlap when cells are genetically altered outside the body and then returned.

Cell therapy: transferring cells

The American Society of Gene & Cell Therapy’s patient education site defines cell therapy as the transfer of a specific cell type or types into a person to treat or prevent a disease. The cells can come from two places:

• Autologous cells: collected from the patient’s own body.
• Allogeneic cells: taken from a matched donor.

The choice affects how a product is made and for whom. A product built from a patient’s own cells is made for that one person.

Gene therapy: correcting or adding genetic instructions

MedlinePlus, the US National Library of Medicine’s health site, explains that gene therapy uses genes to treat or prevent disease by correcting genetic problems. It describes two delivery routes:

1. Ex vivo: cells are removed from the body, modified by adding genetic material, and placed back into the body.
2. In vivo: genetic material is delivered directly into the body, often through an injection.

Genome editing is a separate strategy. Instead of adding new genetic material to cells, it changes the DNA that is already in them. Readers who want detail on one widely discussed delivery vehicle can read AAV Gene Therapy: What It Is, How It Works, and What Patients Need To Know In 2026 – Biolifetechnologies.

Where the two meet: CAR T

MedlinePlus states that cell-based gene therapy combines the two approaches, and it gives CAR T cell therapy as an example. In CAR T therapy, the patient’s immune cells called T-cells are modified by adding receptors. The cells are then returned to the body to recognise and kill cancer cells, according to the ASGCT patient education pages. The practical lesson is that the labels describe a spectrum. A treatment can be a cell therapy, a gene therapy or both, so check what is actually being delivered and how.

Approved therapies and the conditions they treat

Approved products are still concentrated in a small set of conditions. MedlinePlus notes that gene therapies are currently approved only for a small number of diseases, such as Leber congenital amaurosis and spinal muscular atrophy. The table below lists cell-based products named by ASGCT, with the indications it gives.

Indications are summarised from the ASGCT patient education page on cell therapy; the exact labelled wording is set by the regulator, so treat the table as an orientation tool, not eligibility advice.

Decisions follow from the table. Blood cancers, inherited blood disorders and a rare childhood metabolic condition make up most of the entries. Age limits matter: Kymriah’s leukemia indication is for people under 25, and Casgevy and Lyfgenia are approved from age 12. And a product’s approval for one disease does not carry over to others. As the European Gene & Cell Therapy initiative puts it, there is no single gene and cell therapy, any more than there is a single surgery.

Safety risks and what the evidence shows

The main risks differ with the approach, and a patient should weigh them alongside the benefit for their own condition.

• Immune reaction: MedlinePlus warns that the body may see the new genetic material as a threat and react to it.
• Unintended DNA effects: changes to DNA could affect other genes in harmful ways, which is why gene-editing and gene-addition products are assessed so carefully.
• Conditioning: before some cell therapies, patients receive conditioning, which ASGCT says is often chemotherapy and can be extremely hard on the body. Ask what preparation is required, not only what the product is.
• Cytokine release syndrome (CRS): this is a recognised complication tracked in CAR T and related cell therapy trials. Friends of Cancer Research points to the need for a standardized, consistent approach to defining and recording CRS across trials, and it lists a 2021 white paper and a 2022 Cytotherapy paper on the subject. Consistent definitions make it possible to compare safety between products, so check which CRS grading a trial used before comparing numbers.

On benefit, ASGCT says early studies have shown cell and gene therapy can help slow or completely stop certain inherited disorders. That statement is qualitative. It does not give response rates or durability for any product, so use it as a signal of promise and rely on a product’s own trial data for figures. Patients should discuss their specific condition and the treatment centre’s experience with their clinician.

Manufacturing, cost and access

These treatments are hard to produce and deliver. The European Gene & Cell Therapy initiative notes that gene and cell therapy relies on altering millions of cells to have a successful effect, which sets a high bar for consistency in each batch. For autologous products, that work is carried out for one patient at a time using that patient’s own cells.

Why the price is so high

MedlinePlus is direct about the outcome: gene therapies are often expensive and are not widely accessible. The pack does not itemise a price breakdown, but the factors it describes all push in the same direction. Each product is tailored to the disorder it treats, large numbers of cells must be altered, and a study that shows promise in trials may take several years to receive full regulatory approval, with possible further delay before a public health service can offer it. Researchers are also working on the cost side: a 2025 peer-reviewed article in the Journal for ImmunoTherapy of Cancer examines flexible approaches to manufacturing and cost recovery to widen access.

What this means for patients and planners

Access depends on more than approval. A patient may need to be at a treatment centre able to collect cells, administer conditioning and monitor recovery. Health planners have to decide how to fund a high up-front treatment. Digital tools may help with some logistics and decision-making, a theme explored in The Future Of AI In Healthcare: Transformations, Challenges, And What To Expect By 2030 – Biolifetechnologies. Whether a given tool helps will depend on the use case.

Frequently asked questions